View Item 

Show simple item record

Cranial nerve outcomes in regionally recurrent head & neck melanoma after sentinel lymph node biopsy
dc.contributor.authorHanks, John E.
dc.contributor.authorYalamanchi, Pratyusha
dc.contributor.authorKovatch, Kevin J.
dc.contributor.authorAli, S. Ahmed
dc.contributor.authorSmith, Joshua D.
dc.contributor.authorDurham, Alison B.
dc.contributor.authorBradford, Carol R.
dc.contributor.authorMalloy, Kelly M.
dc.contributor.authorMcLean, Scott A.
dc.date.accessioned2020-07-02T20:34:56Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2020-07-02T20:34:56Z
dc.date.issued2020-07
dc.identifier.citationHanks, John E.; Yalamanchi, Pratyusha; Kovatch, Kevin J.; Ali, S. Ahmed; Smith, Joshua D.; Durham, Alison B.; Bradford, Carol R.; Malloy, Kelly M.; McLean, Scott A. (2020). "Cranial nerve outcomes in regionally recurrent head & neck melanoma after sentinel lymph node biopsy." The Laryngoscope 130(7): 1707-1714.
dc.identifier.issn0023-852X
dc.identifier.issn1531-4995
dc.identifier.urihttps://hdl.handle.net/2027.42/156007
dc.publisherJohn Wiley & Sons, Inc.
dc.subject.othersentinel lymph node biopsy
dc.subject.otherhead and neck cutaneous melanoma
dc.subject.othercranial nerve
dc.subject.otherMelanoma
dc.titleCranial nerve outcomes in regionally recurrent head & neck melanoma after sentinel lymph node biopsy
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/156007/1/lary28243.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/156007/2/lary28243_am.pdf
dc.identifier.doi10.1002/lary.28243
dc.identifier.sourceThe Laryngoscope
dc.identifier.citedreferenceCorrigan, M.A., Coffey, J.C., O’Sullivan, M.J., Fogarty, K.M., Redmond, H.P. Sentinel lymph node biopsy: is it possible to reduce false negative rates by excluding patients with nodular melanoma? Surgeon, 2006. 4 ( 3 ): p. 153 ‐ 157.
dc.identifier.citedreferenceLeong, S.P., Kashani‐Sabet, M., Desmond, R.A., et al. Clinical significance of occult metastatic melanoma in sentinel lymph nodes and other high‐risk factors based on long‐term follow‐up. World J Surg, 2005. 29 ( 6 ): p. 683 ‐ 691.
dc.identifier.citedreferenceNowecki, Z.I., Rutkowski, P., Nasierowska‐Guttmejer, A., Ruka W. Survival analysis and clinicopathological factors associated with false‐negative sentinel lymph node biopsy findings in patients with cutaneous melanoma. Ann Surg Oncol, 2006. 13 ( 12 ): p. 1655 ‐ 1663.
dc.identifier.citedreferenceCascinelli, N., Bombardieri, E., Bufalino, R., et al. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two‐step prognostic indicators of survival. J Clin Oncol, 2006. 24 ( 27 ): p. 4464 ‐ 4471.
dc.identifier.citedreferenceKettlewell, S., Moyes, C., Bray, C., et al. Value of sentinel node status as a prognostic factor in melanoma: prospective observational study. Bmj, 2006. 332 ( 7555 ): p. 1423.
dc.identifier.citedreferenceEmery, R.E., Stevens, J.S., Nance, R.W., Corless, C.L., Vetto, J.T. Sentinel node staging of primary melanoma by the "10% rule": pathology and clinical outcomes. Am J Surg, 2007. 193 ( 5 ): p. 618 ‐ 622; discussion 622.
dc.identifier.citedreferenceRiber‐Hansen, R., Abrahamsen, H.N., Sorensen, B.S., Hamilton‐Dutoit, S.J., Steiniche, T. Quantitative real‐time RT‐PCR in sentinel lymph nodes from melanoma patients. Detection of melanocytic mRNA predicts disease‐free survival. Apmis, 2008. 116 ( 3 ): p. 199 ‐ 205.
dc.identifier.citedreferenceTestori, A., De Salvo, G.L., Montesco, M.C., et al. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM‐IMI). Ann Surg Oncol, 2009. 16 ( 7 ): p. 2018 ‐ 2027.
dc.identifier.citedreferenceScoggins, C.R., Martin, R.C., Ross, M.I., et al. Factors associated with false‐negative sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol, 2010. 17 ( 3 ): p. 709 ‐ 717.
dc.identifier.citedreferenceVeenstra, H.J., Wouters, M.W., Kroon, B.B., Olmos, R.A., Nieweg, O.E. Less false‐negative sentinel node procedures in melanoma patients with experience and proper collaboration. J Surg Oncol, 2011. 104 ( 5 ): p. 454 ‐ 457.
dc.identifier.citedreferenceJones, E.L., Jones, T.S., Pearlman, N.W., et al. Long‐term follow‐up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result. JAMA Surg, 2013. 148 ( 5 ): p. 456 ‐ 461.
dc.identifier.citedreferenceStoffels, I., Boy, C., Poppel, T., et al. Association between sentinel lymph node excision with or without preoperative SPECT/CT and metastatic node detection and disease‐free survival in melanoma. Jama, 2012. 308 ( 10 ): p. 1007 ‐ 1014.
dc.identifier.citedreferenceDoepker, M.P., Yamamoto, M., Applebaum, M.A., et al. Comparison of Single‐Photon Emission Computed Tomography‐Computed Tomography (SPECT/CT) and Conventional Planar Lymphoscintigraphy for Sentinel Node Localization in Patients with Cutaneous Malignancies. Ann Surg Oncol, 2017. 24 ( 2 ): p. 355 ‐ 361.
dc.identifier.citedreferenceTrinh, B.B., Chapman, B.C., Gleisner, A., et al. SPECT/CT Adds Distinct Lymph Node Basins and Influences Radiologic Findings and Surgical Approach for Sentinel Lymph Node Biopsy in Head and Neck Melanoma. Ann Surg Oncol, 2018. 25 ( 6 ): p. 1716 ‐ 1722.
dc.identifier.citedreferenceRosko, A.J., Vankoevering, K.K., McLean, S.A., Johnson, T.M., Moyer, J.S. Contemporary Management of Early‐Stage Melanoma: A Systematic Review. JAMA Facial Plast Surg, 2017. 19 ( 3 ): p. 232 ‐ 238.
dc.identifier.citedreferenceBron, L.P., Traynor, S.J., McNeil, E.B., O’Brien, C.J. Primary and metastatic cancer of the parotid: comparison of clinical behavior in 232 cases. Laryngoscope, 2003. 113 ( 6 ): p. 1070 ‐ 1075.
dc.identifier.citedreferenceSchadendorf, D., van Akkooi, A.C.J., Berking, C., et al. Melanoma. Lancet, 2018. 392 ( 10151 ): p. 971 ‐ 984.
dc.identifier.citedreferenceKandel, M., Allayous, C., Dalle, S., et al. Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort. Eur J Cancer, 2018. 105: p. 33 ‐ 40.
dc.identifier.citedreferencePolkowska, M., Ekk‐Cierniakowski, P., Czepielewska, E., Kozlowska‐Wojciechowska, M. Efficacy and safety of BRAF inhibitors and anti‐CTLA4 antibody in melanoma patients‐real‐world data. Eur J Clin Pharmacol, 2018.
dc.identifier.citedreferenceSmith, M.J.F., Smith, H.G., Joshi, K., et al. The impact of effective systemic therapies on surgery for stage IV melanoma. Eur J Cancer, 2018. 103: p. 24 ‐ 31.
dc.identifier.citedreferenceCarreau, N.A., Pavlick, A.C. Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma. Future Oncol, 2018.
dc.identifier.citedreferenceLong, G.V., Hauschild, A., Santinami, M., et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma. N Engl J Med, 2017. 377 ( 19 ): p. 1813 ‐ 1823.
dc.identifier.citedreferenceEggermont, A.M.M., Chiarion‐Sileni, V., Grob, J.J., et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med, 2016. 375 ( 19 ): p. 1845 ‐ 1855.
dc.identifier.citedreferenceEggermont, A.M.M., Blank, C.U., Mandala, M., et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med, 2018. 378 ( 19 ): p. 1789 ‐ 1801.
dc.identifier.citedreferenceWeber, J., Mandala, M., Del Vecchio, M., et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med, 2017. 377 ( 19 ): p. 1824 ‐ 1835.
dc.identifier.citedreferenceLinardou, H., Gogas, H. Toxicity management of immunotherapy for patients with metastatic melanoma. Ann Transl Med, 2016. 4 ( 14 ): p. 272.
dc.identifier.citedreferenceBalch, C. M., Gershenwald, J. E., Soong, S. J., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol, 2009. 27 ( 36 ): p. 6199 ‐ 6206.
dc.identifier.citedreferenceCoit, D.G., Thompson, J.A., Albertini, M.R., et al. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology, Cutaneous Melanoma. V.1.2019. 2018 [cited 2019 January 23, 2019]. https://jnccn.org/view/journals/jnccn/17/4/article-p367.xml
dc.identifier.citedreferenceBalch, C.M., Gershenwald, J. E., Soong, S.J., et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol, 2010. 28 ( 14 ): p. 2452 ‐ 2459.
dc.identifier.citedreferenceReintgen, M., Murray, L., Akman, K., et al. Evidence for a better nodal staging system for melanoma: the clinical relevance of metastatic disease confined to the sentinel lymph nodes. Ann Surg Oncol, 2013. 20 ( 2 ): p. 668 ‐ 674.
dc.identifier.citedreferenceLeung, A.M., Morton, D.L., Ozao‐Choy, J., et al. Staging of regional lymph nodes in melanoma: a case for including nonsentinel lymph node positivity in the American Joint Committee on Cancer staging system. JAMA Surg, 2013. 148 ( 9 ): p. 879 ‐ 884.
dc.identifier.citedreferenceSchmalbach, C.E., Bradford, C.R., Completion lymphadenectomy for sentinel node positive cutaneous head & neck melanoma. Laryngoscope Investig Otolaryngol, 2018. 3 ( 1 ): p. 43 ‐ 48.
dc.identifier.citedreferenceFaries, M.B., Thompson, J.F., Cochran, A.J., et al. Completion Dissection or Observation for Sentinel‐Node Metastasis in Melanoma. N Engl J Med, 2017. 376 ( 23 ): p. 2211 ‐ 2222.
dc.identifier.citedreferenceLeiter, U., Stadler, R. Mauch, C. et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG‐SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol, 2016. 17 ( 6 ): p. 757 ‐ 767.
dc.identifier.citedreferenceMorton, D.L., Thompson, J.F., Cochran, A.J., et al. Final trial report of sentinel‐node biopsy versus nodal observation in melanoma. N Engl J Med, 2014. 370 ( 7 ): p. 599 ‐ 609.
dc.identifier.citedreferenceGershenwald, J.E., Thompson, W., Mansfield, P.F., et al. Multi‐institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol, 1999. 17 ( 3 ): p. 976 ‐ 983.
dc.identifier.citedreferenceMorton, D.L., Wanek, L., Nizze, J.A., Elashoff, R.M., Wong, J.H. Improved long‐term survival after lymphadenectomy of melanoma metastatic to regional nodes. Analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg, 1991. 214 ( 4 ): p. 491 ‐ 499; discussion 499‐501.
dc.identifier.citedreferenceErman, A.B., Collar, R.M., Griffith, K.A., et al. Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma. Cancer, 2012. 118 ( 4 ): p. 1040 ‐ 1047.
dc.identifier.citedreferenceLeong, S.P., Accortt, N.A., Essner, R., et al. Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients. Arch Otolaryngol Head Neck Surg, 2006. 132 ( 4 ): p. 370 ‐ 373.
dc.identifier.citedreferenceChao, C., Wong, S.L., Edwards, M.J., et al. Sentinel lymph node biopsy for head and neck melanomas. Ann Surg Oncol, 2003. 10 ( 1 ): p. 21 ‐ 66.
dc.identifier.citedreferenceMayrovitz, H.N., Ryan, S., Hartman, J.M. Usability of advanced pneumatic compression to treat cancer‐related head and neck lymphedema: A feasibility study. Head Neck, 2018. 40 ( 1 ): p. 137 ‐ 143.
dc.identifier.citedreferenceRockson, S.G. Lymphedema in Head and Neck Cancer. Lymphat Res Biol, 2016. 14 ( 4 ): p. 197.
dc.identifier.citedreferenceRidner, S.H., Dietrich, M.S., Sonis, S.T., Murphy, B. Biomarkers associated with lymphedema and fibrosis in patients with cancer of the head and neck. Lymphat Res Biol, 2018.
dc.identifier.citedreferenceDoke, K.N., Bowman, L., Shnayder, Y., et al. Quantitative clinical outcomes of therapy for head and neck lymphedema. Adv Radiat Oncol, 2018. 3 ( 3 ): p. 366 ‐ 371.
dc.identifier.citedreferencePigott, A., Nixon, J., Fleming, J., Porceddu, S. Head and neck lymphedema management: Evaluation of a therapy program. Head Neck, 2018. 40 ( 6 ): p. 1131 ‐ 1137.
dc.identifier.citedreferenceSchmalbach, C.E., and Bradford, C.R. Is sentinel lymph node biopsy the standard of care for cutaneous head and neck melanoma? Laryngoscope, 2015. 125 ( 1 ): p. 153 ‐ 160.
dc.identifier.citedreferenceCarlson, G.W., Murray, D.R., Lyles, R.H., Hestley, A., Cohen, C. Sentinel lymph node biopsy in the management of cutaneous head and neck melanoma. Plast Reconstr Surg, 2005. 115 ( 3 ): p. 721 ‐ 728.
dc.identifier.citedreferenceSchmalbach, C.E., Nussenbaum, B., Rees, R.S., Schwartz, J., Johnson, T.M., Bradford, C.R. Reliability of sentinel lymph node mapping with biopsy for head and neck cutaneous melanoma. Arch Otolaryngol Head Neck Surg, 2003. 129 ( 1 ): p. 61 ‐ 65.
dc.identifier.citedreferencePicon, A.I., Coit, D.G., Shaha, A.R., et al. Sentinel Lymph Node Biopsy for Cutaneous Head and Neck Melanoma: Mapping the Parotid Gland. Ann Surg Oncol, 2016. 23 ( Suppl 5 ): p. 9001 ‐ 9009.
dc.identifier.citedreferenceWells, K.E., Stadelmann, W.K., Rapaport, D.P., Hamlin, R., Cruse, C.W., Reintgen, D. Parotid selective lymphadenectomy in malignant melanoma. Ann Plast Surg, 1999. 43 ( 1 ): p. 1 ‐ 6.
dc.identifier.citedreferenceFaries, M.B., Thompson, J. F., Cochran, A., et al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol, 2010. 17 ( 12 ): p. 3324 ‐ 3329.
dc.identifier.citedreferenceWertz, A.P., Durham, A.B., Malloy, K.M., Johnson, T.M., Bradford, C.R., McLean, S.A. Total versus superficial parotidectomy for stage III melanoma. Head Neck, 2017. 39 ( 8 ): p. 1665 ‐ 1670.
dc.identifier.citedreferenceNational Comprehensive Cancer Network. Cancer references and guidelines. Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed January 2011.
dc.identifier.citedreferenceShuman, A.G., Fins, J.J., Prince, M.E. Improving end‐of‐life care for head and neck cancer patients. Expert Rev Anticancer Ther, 2012. 12 ( 3 ): p. 335 ‐ 343.
dc.identifier.citedreferenceThom, J.J., Moore, E.J., Price, D.L., Kasperbauer, J.L., Starkman, S.J., Olsen, K.D. The Role of Total Parotidectomy for Metastatic Cutaneous Squamous Cell Carcinoma and Malignant Melanoma. JAMA Otolaryngol Head Neck Surg, 2014. 140 ( 6 ): p. 548 ‐ 554.
dc.identifier.citedreferenceMorton, D.L., Thompson, J.F., Cochran, A.J., et al. Sentinel‐node biopsy or nodal observation in melanoma. N Engl J Med, 2006. 355 ( 13 ): p. 1307 ‐ 1317.
dc.identifier.citedreferenceCoit, D. The Enigma of Regional Lymph Nodes in Melanoma. N Engl J Med, 2017. 376 ( 23 ): p. 2280 ‐ 2281.
dc.identifier.citedreferenceSarnaik, A.A., Zager, J.S., Sondak, V.K. Point: Surgical Management of Lymph Node Basin in Sentinel Lymph Node‐Positive Melanoma. Oncology (Williston Park), 2016. 30 ( 10 ): p. 891 ‐ 892, 895.
dc.identifier.citedreferenceO’Brien, C.J., Uren, R.F., Thompson, J.F., et al. Prediction of potential metastatic sites in cutaneous head and neck melanoma using lymphoscintigraphy. Am J Surg, 1995. 170 ( 5 ): p. 461 ‐ 466.
dc.identifier.citedreferenceWillis, A.I., Ridge, J.A. Discordant lymphatic drainage patterns revealed by serial lymphoscintigraphy in cutaneous head and neck malignancies. Head Neck, 2007. 29 ( 11 ): p. 979 ‐ 985.
dc.identifier.citedreferenceCarlson, G.W. Page, A.J., Cohen, C., et al. Regional recurrence after negative sentinel lymph node biopsy for melanoma. Ann Surg, 2008. 248 ( 3 ): p. 378 ‐ 386.
dc.identifier.citedreferenceKaveh, A.H., Seminara, N.M., Barnes, M.A., et al. Aberrant lymphatic drainage and risk for melanoma recurrence after negative sentinel node biopsy in middle‐aged and older men. Head Neck, 2016. 38 Suppl 1: p. E754 ‐ 60.
dc.identifier.citedreferenceMcMasters, K.M., Reintgen, D.S., Ross, M.I., et al. Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed? Ann Surg Oncol, 2001. 8 ( 3 ): p. 192 ‐ 197.
dc.identifier.citedreferenceJensen, J.D., Gray, R.J., Wasif, N., et al. Can lymphatic drainage of head and neck melanoma be predicted? J Surg Oncol, 2011. 103 ( 8 ): p. 751 ‐ 755.
dc.identifier.citedreferenceShpitzer, T., Segal, K., Schachter, J., et al. Sentinel node guided surgery for melanoma in the head and neck region. Melanoma Res, 2004. 14 ( 4 ): p. 283 ‐ 287.
dc.identifier.citedreferenceParrett, B.M., Kashani‐Sabet, M., Singer, M.I., et al. Long‐term prognosis and significance of the sentinel lymph node in head and neck melanoma. Otolaryngol Head Neck Surg, 2012. 147 ( 4 ): p. 699 ‐ 706.
dc.identifier.citedreferenceHanks, J., Kovatch, K.J., Ali, S.A., et al. Long‐Term Outcomes, Prognostic Value, and Accuracy of Sentinel Lymph Node Biopsy in Head and Neck Melanoma. Oral Presentation. AAO‐HNSF Meeting 2018. Atlanta, GA. October 10 2018. 2018.
dc.identifier.citedreferenceBostick, P., Essner, R., Sarantou, T., et al. Intraoperative lymphatic mapping for early‐stage melanoma of the head and neck. Am J Surg, 1997. 174 ( 5 ): p. 536 ‐ 539.
dc.identifier.citedreferenceFisher S.R., O’Brien CJ. Head and Neck Melanoma, in Cutaneous Melanoma, H.A. Balch CM, Sober AJ, Soong SJ, Editor. 1998, Quality Medical Publishing, Inc: St. Louis. p. 163 – 174.
dc.identifier.citedreferencede Bree, E., de Bree, R. Implications of the MSLT‐1 for sentinel lymph node biopsy in cutaneous head and neck melanoma. Oral Oncol, 2015. 51 ( 7 ): p. 629 ‐ 633.
dc.identifier.citedreferencede Rosa, N., Lyman, G.H., Silbermins, D., et al. Sentinel node biopsy for head and neck melanoma: a systematic review. Otolaryngol Head Neck Surg, 2011. 145 ( 3 ): p. 375 ‐ 382.
dc.identifier.citedreferenceDoting, E.H., de Vries, M., Plukker, J.T., et al. Does sentinel lymph node biopsy in cutaneous head and neck melanoma alter disease outcome? J Surg Oncol, 2006. 93 ( 7 ): p. 564 ‐ 570.
dc.identifier.citedreferenceEvrard, D., Routier, E., Mateus, C., et al. Sentinel lymph node biopsy in cutaneous head and neck melanoma. Eur Arch Otorhinolaryngol, 2018. 275 ( 5 ): p. 1271 ‐ 1279.
dc.identifier.citedreferenceKelly, J., Fogarty, K., Redmond, H.P. A definitive role for sentinel lymph node mapping with biopsy for cutaneous melanoma of the head and neck. Surgeon, 2009. 7 ( 6 ): p. 336 ‐ 339.
dc.identifier.citedreferencePatuzzo, R., Maurichi, A., Camerini, T., et al. Accuracy and prognostic value of sentinel lymph node biopsy in head and neck melanomas. J Surg Res, 2014. 187 ( 2 ): p. 518 ‐ 524.
dc.identifier.citedreferenceSaltman, B.E., Ganly, I., Patel, S.G., et al. Prognostic implication of sentinel lymph node biopsy in cutaneous head and neck melanoma. Head Neck, 2010. 32 ( 12 ): p. 1686 ‐ 1692.
dc.identifier.citedreferenceTeltzrow, T., Osinga, J., Schwipper, V. Reliability of sentinel lymph‐node extirpation as a diagnostic method for malignant melanoma of the head and neck region. Int J Oral Maxillofac Surg, 2007. 36 ( 6 ): p. 481 ‐ 487.
dc.identifier.citedreferenceOllila, D.W., Foshag, L.J., Essner, R., Stern, S.L., Morton, D.L. Parotid region lymphatic mapping and sentinel lymphadenectomy for cutaneous melanoma. Ann Surg Oncol, 1999. 6 ( 2 ): p. 150 ‐ 154.
dc.identifier.citedreferenceFincher, T.R., McCarty, T.M., Fisher, T.L., et al. Patterns of recurrence after sentinel lymph node biopsy for cutaneous melanoma. Am J Surg, 2003. 186 ( 6 ): p. 675 ‐ 681.
dc.identifier.citedreferenceEstourgie, S.H., Nieweg, O.E., Valdes Olmos, R.A., Hoefnagel, C.A., Kroon, B.B. Review and evaluation of sentinel node procedures in 250 melanoma patients with a median follow‐up of 6 years. Ann Surg Oncol, 2003. 10 ( 6 ): p. 681 ‐ 688.
dc.identifier.citedreferenceVuylsteke, R.J., van Leeuwen, P.A., Statius Muller, M.G., Gietema, H.A., Kragt, D.R., Meijer, S. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long‐term follow‐up results. J Clin Oncol, 2003. 21 ( 6 ): p. 1057 ‐ 1065.
dc.identifier.citedreferenceYee, V.S., Thompson, J.F., McKinnon, J.G., et al. Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. Ann Surg Oncol, 2005. 12 ( 6 ): p. 429 ‐ 439.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
lary28243.pdf
Size:
751.3KB
Format:
PDF
View/Open
Name:
lary28243_am.pdf
Size:
850.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.